Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 14;5(3):otad037.
doi: 10.1093/crocol/otad037. eCollection 2023 Jul.

Use of Standardized Inflammatory Bowel Disease Endoscopy Scores in Clinical Practice

Jill K J Gaidos  1 , Badr Al Bawardy  1   2 , Francis A Farraye  3 , Miguel Regueiro  4
Affiliations

Use of Standardized Inflammatory Bowel Disease Endoscopy Scores in Clinical Practice

Jill K J Gaidos et al. Crohns Colitis 360. .

Abstract

Background: Inflammatory bowel disease (IBD) treatment targets include mucosal healing based on standardized endoscopic scoring systems. The rates and ease of use of these scoring systems in practice have not been well described. We aimed to assess the rates and factors associated with the use of IBD endoscopic scoring systems in practice from IBD LIVE attendees.

Methods: IBD Live is an international case-based conference focusing on the management of patients with IBD. We created a web-based survey consisting of 38 questions on the frequency and ease of use of various IBD endoscopic scores. This survey was emailed to the IBD Live listserv in March 2022 with a second email sent 14 days later. We included only respondents who are currently performing endoscopy. Continuous variables were analyzed using an unpaired student's t-test. Categorical variables were analyzed using Pearson's chi-square test.

Results: There were 65 responses out of 170 (38.2% response rate) regular attendees. Eleven responses were excluded (4 with no response on the use of endoscopy scores, and 7 were not performing endoscopy). Of the respondents, 72.2% are from the United States, 70.4% are adult gastroenterologists, 53.9% in academic practice, and 40.7% in practice for ≥15 years. Of the endoscopy scores used ≥50% of the time, 74.1% were using the Mayo Endoscopic Subscore (MES), 72.3% using the Rutgeerts Score, 61.2% using the Simple Endoscopic Score for Crohn's Disease, and 28.6% using the Pouchitis Disease Activity Index. Attending IBD LIVE ≥ monthly (P = .028), attending an IBD conference at least every 2 years (P = .020), and having the scoring system incorporated into the endoscopy documentation software (P = .002) were associated with more consistent use of the MES. Attending IBD Live at least monthly (P = .026), having an IBD volume of ≥50% (P = .011), and attending an IBD conference at least every 2 years (P = .004) was associated with more frequent use of the Rutgeerts score. There were no factors that increased the use of other endoscopic scores.

Conclusions: The MES and the Rutgeerts score are more commonly used with much lower rates of use of endoscopic scores for Crohn's disease and pouchitis. The use of these endoscopy scores is more common among those who regularly attend IBD conferences, have higher volume IBD practices, and have these scoring systems incorporated into endoscopy software. Further evaluation of barriers to use and ways to improve utilization of endoscopic scoring for Crohn's disease and pouchitis is needed.

Keywords: Crohn’s disease; endoscopy scores; inflammatory bowel disease; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

J.K.J.G.: AbbVie Speaker Bureau; Advisory Board: Pfizer. B.A.B: Speaker honoraria: AbbVie, Takeda. Advisory board: Bristol Meyers Squibb. F.A.F: Advisory Boards: AbbVie, BMS, Braintree Labs, IBD Educational Group, Iterative Scopes, Janssen, Pfizer, Sebela. Data Safety Monitoring Boards: Adiso Therapeutics, Lilly. M.R.: Advisory Boards and Consultant (both) for Abbvie, Janssen, UCB, Takeda, Pfizer, BMS, Organon, Amgen, Genentech, Gilead, Salix, Prometheus, Lilly, Celgene, TARGET Pharma Solutions, Trellis. J.K.J.G. holds the position of Associate Editor for Crohn’s & Colitis 360 and has been recused from reviewing or making decisions for the manuscript. M.R. holds the position of Editor-in-Chief for Crohn’s & Colitis 360 and has been recused from reviewing or making decisions for the manuscript.

Figures

Figure 1.
Figure 1.
Frequency of utilizing inflammatory bowel disease endoscopic scores ≥50% of the time. MES, Mayo Endoscopic Subscore; PDAI, Pouchitis Disease Activity Index; SES-CD, Simple Endoscopic Score for Crohn’s disease.
See this image and copyright information in PMC

References

    1. Lee JS, Kim ES, Moon W.. Chronological review of endoscopic indices in inflammatory bowel disease. Clin Endosc. 2019;52(2):129-136. - PMC - PubMed
    1. Sturm A, Maaser C, Calabrese E, et al. ECCO-ESGAR GUIDELINE FOR DIAGNOSTIC ASSESSMENT in IBD Part 2: IBD scores and general principles and technical aspects. J Crohn’s Colitis. 2018;13(3):273-284. - PubMed
    1. Turner D, Ricciuto A, Lewis A, et al. ; International Organization for the Study of IBD. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-1583. - PubMed
    1. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD.. ACG clinical guideline: ulcerative colitis in adults. Amer J Gastroenterol. 2019;114(3):384-413. - PubMed
    1. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE.. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113(4):481-517. - PubMed

LinkOut - more resources